Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial.
The FRONTIER3 trial (NCT05306418) achieved its co-primary endpoints, demonstrating a statistically significant and superior reduction of treated bleeding episodes with both once-weekly and once-monthly Mim8 versus no prophylaxis treatment and prior coagulation factor prophylaxis treatment in 70 children aged one to 11 years. The drug has also been evaluated in adults and adolescents.
Following the positive data, Novo Nordisk expects to make its Mim8 regulatory submission in 2025.
https://finance.yahoo.com/news/novo-nordisk-haemophilia-drug-stops-173745348.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.